PUBLISHER: Grand View Research | PRODUCT CODE: 1842394
PUBLISHER: Grand View Research | PRODUCT CODE: 1842394
The global hormone replacement therapy market size was estimated at USD 23.58 billion in 2024 and is projected to reach USD 39.42 billion by 2033, growing at a CAGR of 5.8% from 2025 to 2033. The hormone replacement therapy industry is gaining momentum due to the rising prevalence of hormonal disorders, especially among aging populations.
Menopause-related conditions such as hot flashes, night sweats, vaginal dryness, and osteoporosis are fueling demand for effective therapies. For instance, October 2024, StatPearls Publishing reported that HRT was used to manage moderate-to-severe vasomotor symptoms, with the Postmenopausal Estrogen/Progestin Interventions trial of 875 women showing significant symptom reduction in estrogen-alone (OR, 0.42; 95% CI, 0.28-0.62) and estrogen-plus-progestin groups (OR, 0.38; 95% CI, 0.25-0.58) compared to placebo. The study clarified HRT's limited role in chronic disease prevention while highlighting its importance in symptom relief. Growing awareness of male hypogonadism, coupled with rising life expectancy, further expands market adoption.
A study by the Oxford-Royal College of General Practitioners Research and Surveillance Centre, analyzing 1.8 million medical records from 465 general practices, reported that 5,451 women on estrogen-based HRT experienced a 78% reduction in COVID-19 infection and mortality rates. Rising awareness of conditions such as menopause, hypogonadism, and growth hormone deficiency is expanding the patient base. Pharmaceutical companies are introducing innovative therapies to meet demand. For example, in January 2022, Ascendis Pharma A/S received European Commission approval for SKYTROFA, the first once-weekly treatment for pediatric growth hormone deficiency, offering improved adherence and convenience compared to daily injections.
Market growth is further supported by increasing awareness of hormone deficiencies and rare disorders. Organizations like the UK-based Child Growth Foundation provide education, guidance, and support to patients, caregivers, and healthcare providers, enhancing adoption of HRT. Despite this momentum, high treatment costs remain a barrier in certain regions. Annual injectable HRT costs range from USD 288 to USD 1,440 for insured patients and USD 480 to USD 4,800 for uninsured individuals, limiting accessibility. Nevertheless, rising patient awareness, innovative drug delivery methods, and expanded therapeutic applications are expected to sustain long-term growth in the hormone replacement therapy industry.
Global Hormone Replacement Therapy Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hormone replacement therapy market report based on product, route of administration, disease type, and region: